These CMML patients had a significantly lower rate in cytogenetic abnormalities, significantly lower mutational rates in ASXL1 and SETBP1, and a significantly higher rate in muTET2/wtASXL1. The gene discussed is ASXL1; the disease is chronic myelomonocytic leukemia.